Market Blog » The Arora Report Stock Market News

ACOR (ACORDIA) FAMPRIDINE IS NOT A VERY GOOD DRUG EVEN IF IT WORKS AS ADVERTISED

October 14, 2009

The FDA Peripheral and Central Nervous System Drugs Advisory Committee meets today to review ACOR’s Fampridine-SR for improvement of walking in patients with multiple sclerosis . We have been negative on ACOR from the very beginning of Fampridine saga because even if the drug works as ACOR promotes, it is not a very good drug. Moreover, the number of participants in ACOR studies have been relatively small compared to what we think it should be to fully evaluate the risk of seizures. We also think the studies are flawed in how they measure the walking ability. Measurement of anything in

SHORT ON INTC (INTEL)

October 13, 2009

As per our earlier post, we are short on INTC from $21.85. Take partial profits right here at $21.36 and take more profits if the stock goes lower. Tighten the stop. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

$CSX COMMENTARY IS NEGATIVE FOR COAL STOCKS

October 13, 2009

$CSX is a major rail carrier for coal to utilities. The commentary with earnings is negative for coal stocks. Consider opportunistically short selling with tight stops $CNX, $BTU, $ACI, and $MEE. Our other screens are bearish on coal stocks. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

INTC (INTEL) SHORT LEVELS

October 13, 2009

In response to questions, if INTC spikes up , we will consider short selling as the stock approaches $22 and stop over $23. Of course these are the levels for a perfect trade, which is not likely. We will consider shorting at lower levels depending on details of the earnings, guidance and how the stock trades. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number

$NUVA ( NUVASIVE ) PRESENTS A SHORT TERM TRADING OPPORTUNITY

October 12, 2009

NUVA stock has been down today on rumors that JNJ (Johnson & Johnson) will announce a lateral fusion device in the post earnings conference call. JNJ web site shows that the head of its device business will be on the call indicating there may be some truth to the rumor. NuVasive’s main business is lateral fusion devices. If there is no competing device on JNJ call, NUVA is a short term buy, otherwise it is short. The early bird catches the worm; consider listening to the call and immediately entering the position www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE

$INTC (INTEL) IS SELL THE NEWS STORY

October 10, 2009

INTEL reports earnings next week. Commentary from the Wall Street is almost universally positive. In the middle of this bullishness, our screens, especially fund flows, show that the smart money is selling into strength. If the earnings are good, the probability is that the good earnings are the result of replenishing inventory and building additional inventory ahead of Windows 7 launch and the holiday season. If the earnings are not good in this boom inventory build up time, it is a indication of slowing demand compared to anticipation. It appears the profitable trade will be on the short side if

CONSIDER SHORT SELL ON MDT (MEDTRONICS)

October 6, 2009

Consider start scaling in a short position in MDT right here at $36.20. MDT had passed all of our screens for a short sale, but we had been waiting for a trigger that the market pays attention to before entering the trade. Patience in entering short sales is especially important when the overall tape is ripping. Today STJ forecast significantly lower revenues and confirmed our earlier checks that hospitals have been reducing inventory of the medical devices they carry. Now we have the trigger and will add to our short position on spikes up.Various health reform bills have provisions of

CONSIDER BUYING $BRCD (BROCADE) ON DIPS

October 5, 2009

According to WSJ $BRCD has put itself up for sale. $BRCD is not only synergistic but can also be strategic to a number of large technology players. A potential acquisition is likely to be north of $11.50. Consider accumulating $BRCD on dips. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details